Gasherbrum Bio, Inc.
Clinical trials sponsored by Gasherbrum Bio, Inc., explained in plain language.
Biotech subsidiary focused on developing therapies, owned by Structure Therapeutics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to help people with diabetes shed pounds and control blood sugar Results expected Sep 2026 (estimated) May already have reported ↗
-
Daily pill aims to tackle weight and diabetes together
Disease control Recruiting nowThis phase 3 study tests aleniglipron, an oral medication taken once daily, for helping adults with obesity or overweight and type 2 diabetes manage their weight over the long term. Participants receive either aleniglipron or a placebo for 76 weeks. The main goal is to see how mu…
Phase 3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New daily pill could help manage weight for years
Disease control Recruiting nowThis phase 3 trial tests a once-daily oral drug called aleniglipron for chronic weight management in 3600 adults with obesity or overweight who also have a weight-related health condition. Participants take the drug or a placebo for 76 weeks, along with diet and exercise changes.…
Phase 3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC